Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/309% below fair value
$2.72−0.18 (-6.37%)
Close on Nov 17, 2026Market cap $1.46BP/E –Yield –
Recursion Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Recursion Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$350.48M. For fiscal 2025 it was -$371.81M. The highest annual figure on record is -$45.40M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$371.81M | – |
| FY2024 | Dec 31, 2024 | -$359.17M | – |
| FY2023 | Dec 31, 2023 | -$287.78M | – |
| FY2022 | Dec 31, 2022 | -$83.52M | – |
| FY2021 | Dec 31, 2021 | -$158.61M | – |
| FY2020 | Dec 31, 2020 | -$45.40M | – |
| FY2019 | Dec 31, 2019 | -$57.04M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$105.95M | – |
| Q1 FY2026 | Mar 31, 2026 | -$81.10M | – |
| Q4 FY2025 | Dec 31, 2025 | -$46.07M | – |
| Q3 FY2025 | Sep 30, 2025 | -$117.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$76.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$131.96M | – |
| Q4 FY2024 | Dec 31, 2024 | -$115.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$59.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$82.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$102.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$74.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$72.92M | – |
| Q2 FY2023 | Jun 30, 2023 | -$67.47M | – |
| Q1 FY2023 | Mar 31, 2023 | -$73.32M | -194.7% |
| Q4 FY2022 | Dec 31, 2022 | -$44.75M | – |
| Q3 FY2022 | Sep 30, 2022 | -$54.54M | – |
| Q2 FY2022 | Jun 30, 2022 | -$61.62M | – |
| Q1 FY2022 | Mar 31, 2022 | $77.39M | – |
| Q4 FY2021 | Dec 31, 2021 | -$61.16M | -813.4% |
| Q3 FY2021 | Sep 30, 2021 | -$33.05M | – |
| Q2 FY2021 | Jun 30, 2021 | -$33.65M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.76M | – |
| Q4 FY2020 | Dec 31, 2020 | $8.57M | – |
| Q3 FY2020 | Sep 30, 2020 | -$19.46M | – |
| Q2 FY2020 | Jun 30, 2020 | -$16.70M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.82M | – |
See a number that looks wrong?